These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27488873)

  • 1. Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer.
    Kim M; Keam B; Kim TM; Kim HG; Kim JS; Lee SS; Shin SH; Kim MK; Park KU; Kim DW; Yun HJ; Lee JS; Heo DS
    Cancer Res Treat; 2017 Apr; 49(2):416-422. PubMed ID: 27488873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414).
    Tomblyn MB; Goldman BH; Thomas CR; Benedetti JK; Lenz HJ; Mehta V; Beeker T; Gold PJ; Abbruzzese JL; Blanke CD;
    J Thorac Oncol; 2012 May; 7(5):906-12. PubMed ID: 22481235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus.
    Lee DH; Kim HT; Han JY; Lee SY; Yoon SJ; Kim HY; Lee JS
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):83-8. PubMed ID: 17468871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
    Ilson DH; Saltz L; Enzinger P; Huang Y; Kornblith A; Gollub M; O'Reilly E; Schwartz G; DeGroff J; Gonzalez G; Kelsen DP
    J Clin Oncol; 1999 Oct; 17(10):3270-5. PubMed ID: 10506629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.
    Ilson DH
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):22-5. PubMed ID: 15685830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.
    Lee SJ; Kim S; Kim M; Lee J; Park YH; Im YH; Park SH
    BMC Cancer; 2015 Oct; 15():693. PubMed ID: 26468007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus.
    Okuma HS; Iwasa S; Shoji H; Takashima A; Okita N; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y
    Anticancer Res; 2014 Sep; 34(9):5037-41. PubMed ID: 25202088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer.
    Watkins JM; Zauls AJ; Kearney PL; Shirai K; Ruppert BN; Harper JL; Sherman CA; Aguero EG; Reed CE; Sharma AK
    Jpn J Clin Oncol; 2011 Mar; 41(3):334-42. PubMed ID: 21084436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer.
    Janjigian YY; Ku GY; Campbell JC; Shah MA; Capanu M; Kelsen DP; Ilson DH
    Am J Clin Oncol; 2014 Apr; 37(2):126-30. PubMed ID: 23211227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
    Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
    J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer.
    Knox JJ; Wong R; Visbal AL; Horgan AM; Guindi M; Hornby J; Xu W; Ringash J; Keshavjee S; Chen E; Haider M; Darling G
    Cancer; 2010 Sep; 116(17):4023-32. PubMed ID: 20533506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
    Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
    Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.
    Cleary JM; Mamon HJ; Szymonifka J; Bueno R; Choi N; Donahue DM; Fidias PM; Gaissert HA; Jaklitsch MT; Kulke MH; Lynch TP; Mentzer SJ; Meyerhardt JA; Swanson RS; Wain J; Fuchs CS; Enzinger PC
    BMC Cancer; 2016 Jul; 16():468. PubMed ID: 27412386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
    Shah MA; Ramanathan RK; Ilson DH; Levnor A; D'Adamo D; O'Reilly E; Tse A; Trocola R; Schwartz L; Capanu M; Schwartz GK; Kelsen DP
    J Clin Oncol; 2006 Nov; 24(33):5201-6. PubMed ID: 17114652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma.
    Hejna M; Kornek GV; Schratter-Sehn AU; Zach M; Schoder M; Raderer M; Rosen H; Schiessel R; Scheithauer W
    Cancer; 1996 Oct; 78(8):1646-50. PubMed ID: 8859175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer.
    Ruppert BN; Watkins JM; Shirai K; Wahlquist AE; Garrett-Mayer E; Aguero EG; Sherman CA; Reed CE; Sharma AK
    Am J Clin Oncol; 2010 Aug; 33(4):346-52. PubMed ID: 19841574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer.
    Kim JY; Do YR; Park KU; Kim MK; Lee KH; Bae SH; Ryoo HM; Baek JH; Song HS
    Cancer Chemother Pharmacol; 2010 May; 66(1):31-6. PubMed ID: 19763571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report.
    Govindan R; Read W; Faust J; Trinkaus K; Ma MK; Baker SD; McLeod HL; Perry MC
    Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):27-31. PubMed ID: 14569845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
    Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
    Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.